Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
CalciMedica, Inc. (GRAY) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/11/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Consent of Independent Registered Public Accounting Firm",
"Updated Business Description",
"Audited recasted financial statements of Private CalciMedica as of and for the years ended December 31, 2022 and 2021"
08/10/2023 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"CalciMedica Reports Second Quarter 2023 Financial Results and Provides Clinical & Corporate Updates"
06/12/2023 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "CalciMedica Announces Relisting on Nasdaq June 12, 2023 11:30 AM EDT LA JOLLA, Calif., June 12, 2023 - CalciMedica Inc. , a clinical-stage biopharmaceutical company focused on developing therapies for life-threatening inflammatory diseases with high unmet need, today announced that The Nasdaq Stock Market LLC has approved CalciMedica's application for the relisting of the Company's common stock on the Nasdaq Capital Market. The Company's common stock is expected to commence trading on the Nasdaq Capital Market at the opening of trading on Wednesday, June 14, 2023, under the ticker symbol “CALC”. CalciMedica's common stock will continue to trade on the OTCQB until market close on the date before listing on the Nasdaq Stock Market under the ticker symbol “CALC”. “We are pleased that we are r..."
05/15/2023 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"CalciMedica Reports First Quarter 2023 Financial Results and Provides Clinical & Corporate Updates LA JOLLA, CA, May 15, 2023 - CalciMedica Inc. , a clinical-stage biopharmaceutical company focused on developing therapies for life-threatening inflammatory diseases with high unmet need, today reported financial results for the first quarter ended March 31, 2023. “We ended our first quarter as a public company in a strong position, with a cash runway that will last into the second half of 2024,” said Rachel Leheny, Ph.D., Chief Executive Officer of CalciMedica. “We are pleased to have entered the second quarter of 2023 with forward momentum, continuing the work towards our near-term clinical milestones with Auxora in acute pancreatitis and asparaginase-associated pancreatitis for critically ..."
05/05/2023 8-K Quarterly results
04/04/2023 8-K/A Financial Statements and Exhibits  Interactive Data
Docs: "Consent of Independent Registered Public Accounting Firm",
"Audited Financial Statements of CalciMedica, Inc. for the years ended December 31, 2022 and 2021",
"Unaudited Pro Forma Combined Financial Statements"
03/22/2023 8-K Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Sta...
Docs: "AGREEMENT AND PLAN OF MERGER AND REORGANIZATION among: GRAYBUG VISION, INC., a Delaware corporation; CAMARO MERGER SUB, INC., a Delaware corporation; and CALCIMEDICA, INC.,",
"Amended and Restated Certificate of Incorporation of Graybug Vision, Inc",
"Certificate of Amendment, to the Amended and Restated Certificate of Incorporation of Graybug Vision, Inc",
"Certificate of Merger",
"Form of Registration Rights Agreement, by and among CalciMedica, Inc. and the several purchasers signatory thereto",
"Form of Warrant to Purchase Shares of Series D Convertible Preferred Stock of CalciMedica, Inc",
"Warrant to Purchase Common Stock, issued by CalciMedica, Inc. to SG Dan Equity Holdings, LLC",
"Warrant to Purchase Common Stock, issued by CalciMedica, Inc. to SG Dan Equity Holdings, LLC",
"Warrant to Purchase Common Stock, issued by CalciMedica, Inc. to Eric Roberts",
"Warrant to Purchase Common Stock, issued by CalciMedica, Inc. to Fred Middleton"
03/15/2023 8-K Submission of Matters to a Vote of Security Holders, Other Events  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION"
02/09/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
12/28/2022 8-K Quarterly results
11/22/2022 8-K Quarterly results
11/21/2022 8-K Quarterly results
11/10/2022 8-K Quarterly results
Docs: "Graybug Vision Reports Financial Results for the Three and Nine Months Ended September 30, 2022"
08/23/2022 8-K Quarterly results
08/11/2022 8-K Quarterly results
06/21/2022 8-K Quarterly results
06/03/2022 8-K Quarterly results
05/10/2022 8-K Quarterly results
04/18/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "GB-102 is a microparticle formulation of a pan-VEGF inhibitor, sunitinib, for the treatment of wet age-related macular degeneration designed for a twice-per-year intravitreal injection. GB-102 has the potential to also benefit patients with diabetic retinopathy. GB-401 is a first-in-class implant formulation containing a novel prodrug of timolol for the treatment of primary open angle glaucoma designed for a twice-per-year intravitreal injection with a proprietary applicator. GB-501"
03/10/2022 8-K Quarterly results
11/12/2021 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Graybug Vision Announces Financial Results for the Three and Nine Months Ended September 30, 2021, and Recent Corporate Developments"
08/11/2021 8-K Quarterly results
06/04/2021 8-K Quarterly results
05/12/2021 8-K Quarterly results
03/05/2021 8-K Quarterly results
11/12/2020 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits
Docs: "Successfully completed initial public offering — On September 24, 2020, Graybug priced its upsized IPO of 5,625,000 shares of common stock at a public offering price of $16.00 per share, following which the underwriters exercised their option to purchase an additional 843,750 shares, resulting in total gross proceeds of $103.5 million. • Completed GB-102 Phase 2a safety trial in macular edema — Final safety and tolerability results confirm the satisfactory safety profile of GB-102 1mg with no ocular serious adverse events or dose-limiting toxicity reported. • Named three new members to the Board of Directors — Graybug appointed Christina Ackermann, Eric Bjerkholt, and Julie Eastland to its Board of Directors in September 2020. Each new member brings deep expertise as leaders ..."

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy